OCUL May 2024 12.500 put
| Previous close | 3.1000 |
| Open | 3.1000 |
| Bid | 6.9000 |
| Ask | 9.1000 |
| Strike | 12.50 |
| Expiry date | 2024-05-17 |
| Day's range | 3.1000 - 3.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GlobeNewswireOcular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that it has agreed to grant inducement awards to (i) its newly appointed Vice President, Head of Programmin
- GlobeNewswire
Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that it will participate at two investor conferences in May: Citizens JMP Life Sciences Confe
- GlobeNewswire
Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024
2024 OIS Retina and ARVO meetings are being held in Seattle, WashingtonBEDFORD, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, announced multiple presentations at th
